Cargando…

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

OBJECTIVES: To evaluate the long-term efficacy and safety of canakinumab to treat patients with colchicine-resistant familial Mediterranean fever (crFMF) during Epoch 4 (weeks 41 to 113) of the CLUSTER study. METHODS: Patients received open-label canakinumab 150 or 300 mg, every 4 or 8 weeks during...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozen, Seza, Ben-Cherit, Eldad, Foeldvari, Ivan, Amarilyo, Gil, Ozdogan, Huri, Vanderschueren, Steven, Marzan, Katherine, Kahlenberg, J Michelle, Dekker, Elise, De Benedetti, Fabrizio, Koné-Paut, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Autoinflammatory Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509527/ https://www.ncbi.nlm.nih.gov/pubmed/32571870 http://dx.doi.org/10.1136/annrheumdis-2020-217419

Ejemplares similares

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
por: Walker, Ulrich A, et al.
Publicado: (2021)

Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever
por: Van Gorp, Hanne, et al.
Publicado: (2020)

COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI – the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases
por: Bourguiba, Rim, et al.
Publicado: (2022)

Gain-of-function mutations in ALPK1 cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome
por: Kozycki, Christina Torres, et al.
Publicado: (2022)

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015)

Novel heterozygous C243Y A20/TNFAIP3 gene mutation is responsible for chronic inflammation in autosomal-dominant Behçet's disease
por: Shigemura, Tomonari, et al.
Publicado: (2016)

Inflammatory lung disease a potential risk factor for onset of idiopathic inflammatory myopathies: results from a pilot study
por: Helmers, Sevim Barbasso, et al.
Publicado: (2016)

Autoimmune-autoinflammatory rheumatoid arthritis overlaps: a rare but potentially important subgroup of diseases
por: Savic, Sinisa, et al.
Publicado: (2017)

Polymyalgia rheumatica: an autoinflammatory disorder?
por: Floris, Alberto, et al.
Publicado: (2018)

Haploinsufficiency of A20 impairs protein–protein interactome and leads into caspase-8-dependent enhancement of NLRP3 inflammasome activation
por: Rajamäki, Kristiina, et al.
Publicado: (2018)

Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease
por: Kacar, Mark, et al.
Publicado: (2020)

Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome
por: Kuemmerle-Deschner, Jasmin Beate, et al.
Publicado: (2020)

Contrasting role of NLRP12 in autoinflammation: evidence from a case report and mouse models
por: Lévy, Dan, et al.
Publicado: (2021)

Patients with VEXAS diagnosed in a Danish tertiary rheumatology setting have highly elevated inflammatory markers, macrocytic anaemia and negative autoimmune biomarkers
por: Rasch, Mads Nyhuus Bendix, et al.
Publicado: (2022)

Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients
por: Khitri, Mohamed-Yacine, et al.
Publicado: (2022)

Distinct immune-effector and metabolic profile of CD8(+) T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors
por: Benesova, Karolina, et al.
Publicado: (2022)

Potential impact of autoimmune diseases family history in IgG4-related disease: a retrospective cohort study
por: Sun, Ruijie, et al.
Publicado: (2023)

Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis
por: Gao, Hui, et al.
Publicado: (2023)

SAPHO syndrome can cause sausage finger lesions
por: Jiang, Haixu, et al.
Publicado: (2023)

Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism
por: Mascaro, Jose Manuel, et al.
Publicado: (2023)

Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry
por: Vitale, Antonio, et al.
Publicado: (2023)

Characteristics and outcome of critically ill patients with systemic rheumatic diseases referred to the intensive care unit
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2023)

Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry
por: Ruscitti, Piero, et al.
Publicado: (2023)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
por: Berdeli, Afig, et al.
Publicado: (2019)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF
por: Gul, A, et al.
Publicado: (2015)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Clinical Presentation and Pathogenesis of Cold-Induced Autoinflammatory Disease in a Family With Recurrence of an NLRP12 Mutation
por: Borghini, S, et al.
Publicado: (2011)

Long-Term Clinical Profile of Children With the Low-Penetrance R92Q Mutation of the TNFRSF1A Gene
por: Pelagatti, M A, et al.
Publicado: (2011)

Association of the Leukocyte Immunoglobulin‐like Receptor A3 Gene With Neutrophil Activation and Disease Susceptibility in Adult‐Onset Still’s Disease
por: Wang, Mengyan, et al.
Publicado: (2021)

Novel Majeed Syndrome–Causing LPIN2 Mutations Link Bone Inflammation to Inflammatory M2 Macrophages and Accelerated Osteoclastogenesis
por: Bhuyan, Farzana, et al.
Publicado: (2021)

Haploinsufficiency of PSMD12 Causes Proteasome Dysfunction and Subclinical Autoinflammation
por: Yan, Kai, et al.
Publicado: (2022)

Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study
por: Yoshida, Shuhei, et al.
Publicado: (2023)

P02-027 - Quality of life in CAPS treated by Canakinumab
por: Marsaud, C, et al.
Publicado: (2013)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

Development of focal segmental glomerulosclerosis in a patient with Familial Mediterranean Fever resistant to colchicine therapy under treatment with Canakinumab
por: Barut, K, et al.
Publicado: (2015)

A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever
por: Corsia, Alice, et al.
Publicado: (2017)

Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine
por: Andreotti, Felicita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cipj1am4uc67mfrf91p4uvn472